MediciNova dropping MN-305 for insomnia

MediciNova (MNOV; Osaka:4875) said it will discontinue development of MN-305 for insomnia after the compound missed the primary endpoint of a significant reduction in wake time after sleep onset (WASO) in a Phase IIa trial. In the double-blind, U.S. trial, 90 patients with primary insomnia received either 1, 3 or 6 mg of oral MN-305 or placebo at 60 minutes before bedtime on seven consecutive nights. Last year, the serotonin (5-HT1A) receptor agonist missed the primary endpoint in a Phase II/III trial to treat generalized anxiety disorder (GAD) (See BioCentury Extra, Monday, June 12, 2006). ...